Abstract
Diffuse glial neoplasms in adults remain incurable, with high morbidity and mortality, despite significant advances in our understanding of their molecular characteristics and the underlying alterations in specific signaling pathways. With rare exceptions, and unlike the successes in treatment of other solid tumors, successful application of targeted therapies for glial neoplasms has remained elusive. Mutations in the IDH1/2 genes are factors in the neoplastic transformation of a large proportion of intermediate and high-grade gliomas, and a variety of treatment approaches including the development of vaccines and molecular inhibitors are currently being evaluated. Epigenetic factors such as DNA methylation also play an important role in the response to specific therapies. The accurate screening of predictive biomarkers in the diagnosis of gliomas and other tumors of the nervous system is now needed to allow selection of the most appropriate therapeutic approaches based on the molecular characteristics of the tumor.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cagney DN, Sul J, Huang RY, et al. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology. 2017; https://doi.org/10.1093/neuonc/nox242.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.
Velazquez Vega JE, Brat DJ. Incorporating advances in molecular pathology into brain tumor diagnostics. Adv Anat Pathol. 2018;25:143.
Staedtke V, a Dzaye OD, Holdhoff M. Actionable molecular biomarkers in primary brain tumors. Trends Cancer. 2016;2:338–49.
Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas – implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434–52.
Ballester LY, Fuller GN, Powell SZ, et al. Retrospective analysis of molecular and immunohistochemical characterization of 381 primary brain tumors. J Neuropathol Exp Neurol. 2017;76:179–88.
Khan IN, Ullah N, Hussein D, et al. Current and emerging biomarkers in tumors of the central nervous system: possible diagnostic, prognostic and therapeutic applications. Semin Cancer Biol. 2017;17:30114–1.
Chen R, Cohen AL, Colman H. Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr Treat Options in Oncol. 2016;17:42.
Lieberman F. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Res. 2017;6:1892.
Johanns TM, Dunn GP. Applied cancer immunogenomics: leveraging neoantigen discovery in glioblastoma. Cancer J. 2017;23:125–30.
Diamandis P, Aldape KD. Insights from molecular profiling of adult glioma. J Clin Oncol. 2017;35:2386–93.
Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775–88.
Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017;133:5–12.
Mack SC, Pajtler KW, Chavez L, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018;553:101–5.
Kickingereder P, et al. IDH mutation status is associated with a distinct hypoxia angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bonnin, J.M. (2019). Predictive Biomarkers and Targeted Therapies in Adult Brain Cancers. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_34
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)